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In Brief
Group 2 innate lymphoid cells (ILC2s) and
regulatory T (Treg) cells are systemically
induced by helminth infection but also
sustain metabolic homeostasis and
contribute to tissue repair. Locksley and
colleagues describe how the cytokines
IL-33 and IFN-g counter-regulate ILC2
activation to control Treg cell numbers
and type 2 immune responses.
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Group 2 innate lymphoid cells (ILC2s) and regulatory
T (Treg) cells are systemically induced by helminth
infection but also sustain metabolic homeostasis in
adipose tissue and contribute to tissue repair during
injury. Here we show that interleukin-33 (IL-33) medi-
ates activation of ILC2s and Treg cells in resting
adipose tissue, but also after helminth infection or
treatment with IL-2. Unexpectedly, ILC2-intrinsic IL-
33 activation was required for Treg cell accumulation
in vivo and was independent of ILC2 type 2 cytokines
but partially dependent on direct co-stimulatory in-
teractions via ICOSL-ICOS. IFN-g inhibited ILC2 acti-
vation and Treg cell accumulation by IL-33 in infected
tissue, as well as adipose tissue, where repression
increased with aging and high-fat diet-induced
obesity. IL-33 and ILC2s are central mediators of
type 2 immune responses that promote tissue and
metabolic homeostasis, and IFN-g suppresses this
pathway, likely to promote inflammatory responses
and divert metabolic resources necessary to protect
the host.
INTRODUCTION
Allergic, or type 2, immunity occurs in response to parasitic hel-
minths, restricting sites permissive for parasite reproduction and
limiting tissue damage. Such responses involve activation of
group 2 innate lymphoid cells (ILC2s) and adaptive CD4+ Th2
cells, which together secrete the cytokines interleukin-4 (IL-4),
IL-5, and IL-13 necessary for the accumulation of eosinophils
and alternatively activated macrophages (AAMs) in involved
tissues (Walker and McKenzie, 2013). In turn, chronic parasitism
induces regulatory T (Treg) cells, which dampen immune pa-
thology not only in helminth infection, but also in a variety of
mouse and human conditions characterized by excess immuneactivation, such as autoimmunity, graft-versus-host disease,
and metabolic syndrome (Johnston et al., 2014; McSorley and
Maizels, 2012; Wiria et al., 2014). Indeed, one of the key issues
during allergic pathology provoked by common environmental
allergens might be the failure to induce or maintain Treg cells
(Allen and Maizels, 2011). Although transcriptional networks
are establishing connections between Treg cells and the subsets
of effector T cells they restrain (Chaudhry and Rudensky, 2013),
cellular networks that link these effector and regulatory modules
are incompletely understood. Further insights will be important in
considering therapeutic strategies to control chronic pathologic
states characterized by loss (allergy, atopy) or gain (cancer,
chronic infectious diseases) in this regulatory-to-effector cell
balance.
Recent reports have called attention to the confluence of
innate cells associated with type 2 immunity, including ILC2s,
eosinophils, and AAMs, with Treg cells in visceral adipose tissue
(VAT) of resting mice (Cipolletta et al., 2012; Feuerer et al., 2009;
Molofsky et al., 2013; Odegaard et al., 2007; Qiu et al., 2014; Va-
santhakumar et al., 2015; Wu et al., 2011). Maintaining this
cellular architecture is necessary for metabolic homeostasis,
and its loss during obesity is associated with increased inflam-
matory T cells, macrophages, and the development of insulin
resistance and type 2 diabetes. Adipose ILC2s and Treg cells
constitutively express interleukin-1 receptor-like 1, (IL1RL1,
ST2), the regulated subunit of the receptor for the IL-1 family
member IL-33, a cytokine maintained in the nucleus of some
epithelial, endothelial, and mesenchymal cells (Pichery et al.,
2012) (Cayrol andGirard, 2014). IL-33 is released during necrosis
or possibly via other regulated mechanisms, and stimulates
ILC2s to produce cytokines like IL-13 and IL-5, important for
the response to helminths and allergens (Neill et al., 2010). Exog-
enous IL-33 induces expansion of adipose tissue ILC2 and Treg
cells (Molofsky et al., 2013; Vasanthakumar et al., 2015) and
beneficial metabolic effects (Miller et al., 2010), acting in part
via ILC2-mediated induction of ‘‘beige’’ adipose tissue associ-
ated with increased heat production (Brestoff et al., 2014; Lee
et al., 2015). IL-33 administration also expands systemic Treg
cells that suppress the rejection of allogeneic cardiac transplants
(Brunner et al., 2011; Turnquist et al., 2011), and IL-33 promotesImmunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc. 161
resolution of tissue damage in models of colitis (Duan et al.,
2012; Schiering et al., 2014), hepatitis (Liang et al., 2013), cuta-
neous wounding (Yin et al., 2013), central nervous system injury
(Gadani et al., 2015), and atherosclerosis (Miller et al., 2008). On
the basis of these prior findings, here we determine the role of
ILC2s in regulating Treg cells under conditions of elevated
IL-33, including resting adipose tissue and during helminth in-
fection. We found that ILC2-intrinsic IL-33 signaling and ICOSL
expression promoted Treg cell accumulation, whereas the in-
flammatory cytokine IFN-g counter-regulated the effects of
IL-33, in part through direct effects on ILC2s.
RESULTS
Visceral Adipose Tissue IL-33 Promotes ILC2 Function
and Treg Cell Maintenance
Wedocumentedhigh concentrations of IL-33 in adipose tissueas
compared to lung or spleen (Figure 1A), corroborating prior
studies (Miller et al., 2010; Vasanthakumar et al., 2015; Zeyda
et al., 2012). IL-33 was expressed selectively in the nuclei of
many adipose tissue endothelial cells (Figure 1B, Figure S1A
and S1B, data not shown). Althoughwe confirmed IL-33-positive
cells in mouse lung and spleen, where expression has been re-
ported for alveolar type 2 pneumocytes and fibroblastic reticular
cells (FRC), respectively, endothelium from these tissues did not
express IL-33 (Figure S1A, and Pichery et al., 2012). In contrast,
human endothelial expression of IL-33 ismorewidespread (Pich-
ery et al., 2012). VAT ILC2s express IL1RL1 (ST2) and localize
near the adipose tissue vasculature (Figure S1B and Molofsky
et al., 2013) suggesting they might be sensitized by endothelial
IL-33. We used previously described ‘‘Red5’’ IL-5tdtomato-cre re-
porter mice (Nussbaum et al., 2013) to assess the expression of
IL-5 in ILC2without theneed for ex vivo stimulation. ILC2 IL-5pro-
duction was diminished in adipose ILC2s from IL1RL1-deficient
mice (Figure 1C, Figure S1C). Although less numerous than
ILC2s, IL-5+ CD4+ Th2 cells that accumulate in adipose tissue
also showed diminished IL-5 expression in the absence of IL-33
signals (Figures S1D and S1E). Despite their lower IL-5 produc-
tion, the numbers of ILC2s and primed, IL-4-competent CD4+
Th2 cells in VATwere not decreased by the loss of IL-33 signaling
(Figure S1C, data not shown). The attenuated IL-5 expression in
VAT of IL1RL1-deficient mice resulted in a diminution in numbers
of VAT eosinophils, consistent with a biologically relevant effect
that was not evident in blood or lung (Figure 1D).
Treg cells accumulate in VAT of 4- to 6-month-old mice and
express high amounts of GATA3, IL1RL1, KLRG1, and CD25
(Figure 1E, Figure S1F, data not shown), consistent with an acti-
vated or ‘‘effector’’ tissue-resident phenotype (Burzyn et al.,
2013b; Cipolletta et al., 2012; Feuerer et al., 2009; Vasanthaku-
mar et al., 2015). Accumulation of Treg cells was attenuated by
loss of IL-33 signals in VAT, but not in lung or spleen (Figures
1F and 1G, Figure S1G). Even on normal chow diet, IL1RL1-defi-
cient animals develop significant increases in VAT CD8+ T cells
after 12–16 weeks (wild-type 6,801+/1221 cells, IL1RL1-defi-
cient 10,670+/1176 cells, p = 0.03, n = 16–18). Thus, IL-33
promotes VAT ILC2 cytokine expression associated with the
accumulation of VAT eosinophils and activated Treg cells, and
suppresses the accumulation of CD8+ T cells, thus potentially
limiting adipose inflammation and obesity (Miller et al., 2010).162 Immunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc.Next we tested the ability of isolated Treg cells and ILC2s to
respond directly to IL-33. Although splenic Treg cells, which
are largely IL1RL1 at the time of isolation, were not affected
by addition of IL-33 to short-term in vitro suppression assays,
VAT IL1RL1+ Treg cells demonstrated enhanced suppression
in the presence of IL-33, particularly at low Treg-to-Teffector ra-
tios (Figure 2A). Given once in vivo, IL-33 rapidly enhances CD25
expression on VAT IL1RL1+ Treg cells and drives their entry into
the cell cycle (Figures S2A and S2B). VAT IL1RL1+ ILC2 and Th2
also respond to IL-33 by increasing CD25, proliferating, and
increasing IL-5 production, as assessed by MFI of the IL-5 re-
porter (Figures S2C–S2E). Non-IL-5+ CD4+ T cells and NK cells
in VAT do not respond to IL-33 or IL-2 over this time period
(data not shown). Thus, IL-33 can directly promote the prolifera-
tion, activation and function of IL1RL1+ lymphocytes, including
VAT Treg cells, ILC2s, and rare IL-5+ Th2 cells. IL-33 also in-
creases CD25 expression on Treg cells and ILC2s, potentially
increasing their sensitivity to IL-2.
IL-2-Mediated Expansion of Treg Cells and ILC2 Is
Augmented by Endogenous IL-33
Low-dose IL-2 has been used to expand Treg cells and treat
patients with autoimmune disease and graft-versus-host dis-
ease (Liao et al., 2011). ILC2 and Treg cells constitutively ex-
press the high-affinity IL-2 receptor, including CD25 (IL-2Ra),
and both expand in vivo to IL-2 (Van Gool et al., 2014).
Because IL-33 maintains VAT Treg cells and promotes their
expression of CD25 (Figure S2B), we assessed whether sys-
temic responses to IL-2 are reinforced by endogenous IL-33
in vivo. IL-2 promotes systemic expansion of Treg cells that ex-
press IL1RL1 and high levels of CD25 (Figure 2B). IL-2
modestly increased Treg cell cycling (Figure S2F), and the
greatest proliferation occurred in IL1RL1+ Treg cells (Figure 2C).
The IL-2-mediated expansion of VAT and lung Treg cells, and
their upregulation of CD25, was attenuated in IL1RL1-deficient
mice (Figure 2D-E, Figure S2G). Co-administration of IL-33 with
IL-2 further enhanced Treg cell accumulation (Figure S2H).
ILC2 also expanded to IL-2 in VAT and lungs, and expansion
was blunted in both tissues in the absence of IL1RL1 (Fig-
ure 2F). These data show that endogenous tissue IL-33 coop-
erates with IL-2 to promote the expansion of both Treg cells
and ILC2.
ILC2s Mediate IL-33-Dependent Treg Cell Homeostasis
In Vivo
Despite direct effects of IL-33 in promoting IL1RL1+ Treg cells
(Figure 2, Figure S2) (Schiering et al., 2014; Vasanthakumar
et al., 2015), our data did not exclude indirect effects of IL-33
in vivo through its ability to activate ILC2s. Unexpectedly, loss
of ILC2s via IL-5cre-mediated cell deletion (Molofsky et al.,
2013) significantly impaired the age-related Treg cell accumula-
tion in VAT (Figure 3A, Figure S3A); this was particularly apparent
in the IL1RL1+ Treg cell population (Figure 3B). ILC2-deficient
mice displayed no overt signs of autoimmunity and young mice
had normal numbers of VAT, lung, and spleen Treg cells (data
not shown). To assess whether ILC2 were required for IL-33-
mediated induction of Treg cells, we administered IL-33 to mice
rendered ILC2-deficient using IL-5cre or IL-13cre strains crossed
to deleter alleles (Molofsky et al., 2013; Nussbaum et al., 2013).
Figure 1. IL-33 Is an Endothelial Cytokine that Promotes ILC2 IL-5 Production, Eosinophilia, and Treg Cells in Visceral Adipose Tissue
(A) Total tissue IL-33 concentrations measured by ELISA.
(B) VAT immunofluorescence microscopy demonstrating IL-33 and CD31 endothelial cell co-localization in wild-type (WT) but not IL-33-deficient mice.
(C) Quantification of IL-5 reporter (Red5 tdtomato mean fluorescence intensity, MFI) from wild-type or IL1RL1-deficient (Il1rl1/) Il5tdtomato-cre/+ animals.
(D) Enumeration of total eosinophils in the indicated tissues and strains.
(E) Representative flow cytometric plots pre-gated on CD4+ T cells of 4- to 6-month-old male animals with (F) quantification of percent (top) and total per gram
(bottom) FoxP3+ CD4+ Treg cells from the tissues and strains indicated or (G) percent Treg cell expressed as a function of VAT weight. * = p < 0.05, ** = p < 0.01,
*** = p < 0.001, ns = not significant. Data are representative of three or more experiments (A–C, E) or pooled from three or more experiments (D, F, and G). Error
bars represent SEM.
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Figure 2. IL-2 Coordinates with IL-33 to Pro-
mote IL1RL1 (ST2)+ Treg Cells and ILC2
Expansion and Function
(A) VAT FoxP3GFP+ Treg cells from multiple mice
were sort-purified and used in an in vitro sup-
pression assay at the indicated Treg/Teff ratios by
assessing CTV dilution in naive CD4+ T cells in
the presence (red lines) or absence (gray lines) of
IL-33.
(B) Flow cytometric plots pre-gated on CD4+
T cells from the indicated tissues of wild-type (top)
or IL1RL1-deficient (Il1rl1/) mice (bottom)
treated with PBS (left) or IL-2 complexes (right), as
indicated.
(C) Quantitation of Ki-67+ proliferative cells from
the indicated CD4+ T cell subsets of IL-2-treated
mice.
(D–F) FoxP3+ CD4+ Treg cells (D and E) or ILC2 (F)
were quantitated from the indicated tissues after
PBS or IL-2 complexes in wild-type or IL1RL1-
deficientmice, as indicated. Black dots (PBS), gray
dots (IL-2 complex). Data are representative of two
to three experiments (A andB) or pooled from three
experiments (C–F). Error bars represent SEM.IL-33 robustly increased ILC2 in VAT, lung, and spleen of wild-
type mice; IL-33 also promoted Treg cells comparably to IL-2
(Figures S3B and S3C, data not shown). In contrast, in ILC2-defi-
cient mice, IL-33-induced Treg cell expansion was impaired
(Figures 3C–3E, Figure S3D–S3F), and this was particularly
marked in the subset of ‘‘activated’’ GATA3+ IL1RL1+ KLRG1+
Treg cells (data not shown). MyD88 is a shared adaptor for TLR
and IL-1 family signaling and is required for IL-33 signaling. To
assess the cell-intrinsic role of IL-33 signaling in ILC2-directed
Tregcell accumulation,wegave IL-33 tomice lacking the adaptor
protein MyD88 in IL-5+ ILC2s (IL-5tdtomato-cre 3 MyD88 flox). In
multiple tissues, ILC2 expansion and proliferation were impaired164 Immunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc.and Treg cell accumulation was blunted
(Figures 3F–3H, Figure S3G, data not
shown). In contrast, mice lacking MyD88
in FoxP3+ Treg cells (Foxp3YFP-cre 3
Myd88 flox) showed normal proliferation
and accumulation of ILC2 and Treg
cells in response to IL-33, although
a modest reduction in the KLRG1+
IL1RL1+ Treg cell subset was noted
(Figures 3G–3I). These ILC2-mediated
effects of IL-33 on Treg cell accumulation
were not mediated by IL-5, IL-4, IL-13,
or IL-9; Treg cell expansion to IL-33
was normal in mice lacking these cyto-
kines (Figure 3C, Figures S3D and S3E,
data not shown). FoxP3+ Treg cells, in
contrast to CD4+ Th2 cells, did not ex-
press reporters for either IL-5 or IL-13
(data not shown). Thus, ILC2-intrinisic
responses to IL-33, but not ILC2 canoni-
cal cytokines, are required for optimal
IL-33-mediated expansion of Treg cells
in vivo.We next determined whether ILC2s mediate the normal ex-
pansion of Treg cells during helminth infection, a challenge asso-
ciated with elevated IL-33. During primary infection with the
nematodeNippostrongylus brasiliensis, which transiently passes
through the lung before reaching the small intestine, lung
KLRG1+ Treg cell accumulation was significantly diminished in
ILC2-deficient (IL-5 deleter) mice (Figure 3J); similar trends
were observed in mice lacking the adaptor MyD88 in IL-5+ cells
(Figure S3H, data not shown). Although smaller numbers of IL-5-
expressing Th2 cells were also depleted in thesemice, andmight
contribute to these ILC2-dependent effects, we noted that
after secondary helminth infection, accumulation of lung ILC2,
Figure 3. ILC2 Are Required for IL-33- and Helminth-Dependent Treg Cell Accumulation In Vivo
(A) FoxP3+ CD4+ Treg cells from VAT of 2- to 6-month-old male wild-type or IL-5 deleter (Il5tdtomato-cre/tdtomato-cre 3 Rosa26-DTA/DTA) animals expressed as a
correlation with VAT weight.
(B) Representative flow cytometric plots of resting VAT CD4+ T cells from wild-type or IL-5 deleter mice.
(C–E) Percent FoxP3+ Treg cells of CD4+ T cells measured in wild-type, IL-5-deficient (Il5tdtomato-cre/tdtomato-cre), or IL-5 deleter animals after control PBS (black
dots) or IL-33 treatment (gray dots) from the indicated tissues.
(F–I) Cells were enumerated from the indicated tissues (VAT, Lung) and strains (Il5tdtomato-cre/tdtomato-cre or FoxP3YFP-cre/y 3MyD88 flox/flox or flox/+) after three
doses of IL-33 or from untreated controls.
(J and K) Percent KLRG1+ of FoxP3+ Treg cells in lung was enumerated on (J) day 7–8 of primary infection or (K) 2 weeks after secondary infection with
N. brasiliensis from the indicated strains. Data represent three ormore experiments (B) or pooled from two (J and K) or three ormore experiments (A, C–I). Note the
double y axis in (F). Error bars represent SEM.but not total CD4+ Th2 cells, remained impaired in IL-33-defi-
cient and IL-5 deleter mice (Figures S3I and S3J). KLRG1+
Treg cells proportionately increased in lung, mesenteric lymphnode (MLN) and VAT, and optimal accumulation depended on
both IL-33 signaling and IL-5+ ILC2s (Figure 3K, Figures S3K
and S3L). Thus, IL-33, whether induced endogenously inImmunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc. 165
Figure 4. ILC2 and Treg Cells Co-Localize In Vivo
(A–C) Representative immunofluorescence microscopy images of lung under resting conditions (Resting), after IL-33 administration33 doses (IL-33), or 2 weeks
afterN. brasiliensis infection (Helminth) identifying IL-5+ (tdtomato+) cells, FoxP3+ (GFP+) cells, and (B and C) KLRG1+ cells from Red5 (Il5tdtomato-cre/+) Foxp3GFP
double reporter animals.
(D) Quantification of total FoxP3GFP+ cells and IL-5+ ILC2 (top) or percent FoxP3GFP+ of CD4+ T cells and total IL-5+ ILC2 (bottom) per high-powered field (4003
total magnification). Data are expressed as total or percent FoxP3+ Treg cells per IL-5+ ILC2 and grouped as bins. (A–D) Representative data from two exper-
iments with two or mice per group. Error bars represent SEM.response to migratory helminths or provided exogenously, pro-
moted ILC2-dependent increases in ‘‘activated’’ Treg cells in
multiple tissues.
ILC2 and Treg Cells Interact In Vitro and In Vivo
IL-5+ ILC2 andKLRG1+ FoxP3+ Treg cells localize to similar areas
of the lung and VAT under resting conditions and in multiple166 Immunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc.tissues after induction by IL-33 or helminth infection (Figures
4A–4D, Figure S4A–S4E), suggesting these cells may interact
in vivo. The co-stimulatory protein ICOS was reported to func-
tion in sustaining tissue Treg cells, as opposed to the role
for IL-2 in promoting Treg cell survival in lymphoid organs
(Smigiel et al., 2014). When assessed directly ex vivo, ILC2s ex-
press ICOS ligand (ICOSL) at amounts comparable to B cells
Figure 5. ILC2 ICOSL Engages Treg Cell ICOS to Promote Treg Cell Tissue Accumulation
(A and B) Flow cytometric analysis of (A) ICOSL or (B) ICOS, KLRG1, and IL1RL1 expression from the indicated tissues and populations.
(C–E) In vitro 3 day culture of (C) KLRG1+ Treg cells ± ILC2, (D) KLRG1+ Treg, KLRG1 Treg, or naive CD4+ T cells alone ± agonist ICOS antibody, or (E) CD4+
populations indicated co-cultured with ILC2 ± blocking ICOSL antibody, enumerating Treg cell survival.
(F and G) Treatment with three doses of IL-33 (gray dots) or control PBS (black dots) and (F) total ILC2 or ILC2 per g (VAT), (G) eosinophils, or (H) percent FoxP3+
Treg cells of CD4+ T cells were enumerated from wild-type and ICOSL deficient (Icosl/) animals. Data are representative of two to three experiments (A–E) or
pooled from two or more experiments (F–H). Error bars represent SEM.(Figure 5A); expression is particularly high in VAT (Figure S5A).
ICOSL was also expressed on the small numbers of IL-5+
KLRG1+ GATA3-hi Th2 cells in VAT, but not on CD8+ T cells,
FoxP3+ CD4+ Treg, other CD4+ T cells, or NK cells (Figures S5B
and S5C; and data not shown). In peripheral tissues, Treg cells
comprised the major ICOShi lymphocytes, and, among these,
KLRG1+ IL1RL1+ Treg cells were uniformly ICOShi (Figure 5B).
ICOShi Treg cells have been associated with IL-2 therapy, hel-
minth infection, and neoplasms, and are activated and highlysuppressive Treg cells (Busse et al., 2012; Redpath et al., 2013;
Sim et al., 2014).
After administration of IL-33 or infection with N. brasiliensis,
ICOSL+ ILC2 and ICOShi Treg cells accumulate in tissues and
persist for prolonged periods (Figures S5D–S5F, data not
shown). Although ILC2 and Th2 both express ICOS, the ex-
pression was much lower than on Treg cells, was inversely cor-
related with ICOSL expression, and was induced in response
to IL-2 but not IL-33 (data not shown). Genetic deficiency orImmunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc. 167
antibody blockade of ICOSL led to increased lymphocyte ex-
pression of ICOS (data not shown), suggesting the possibility
of ICOSL/ICOS shedding after binding.Whereas ICOS activation
(agICOS) supported KLRG1+ Treg cell survival in vitro, co-culture
of ILC2 and KLRG1+ IL1RL1+ Treg cells, but not other CD4+ lym-
phocytes, promoted Treg cell survival that was blocked by
ICOSL antibody (aICOSL) (Figures 5C–5E). Following adminis-
tration of systemic IL-33, ILC2 and eosinophil expansion was
normal in ICOSL-deficient mice, but Treg cell expansion was
impaired (Figures 5F–5H). In VAT there was a trend toward
impaired total Treg cell accumulation (p = 0.1, data not shown).
We conclude that ILC2s can interact with ICOShi, KLRG1+ Treg
cells and promote Treg cell accumulation via ICOSL-ICOS inter-
actions, although additional mechanism(s) also contribute,
particularly in VAT. After secondary helminth infection, a subset
of IL-5+ Th2 cells that express ICOSL also increase (Figures
S5D–S5F) and may contribute additionally to enhance Treg cell
accumulation.
Interferon-g Inhibits ILC2 Activation by IL-33
Although VAT IL-33 is increased in obesity (data not shown and
Zeyda et al., 2012), ILC2s, Treg cells, eosinophils, and AAMs
decline (Feuerer et al., 2009; Molofsky et al., 2013), suggesting
that loss of IL-33 does not account for this effect. However,
interferon-g-producing T cells and NK cells increase in obese
VAT and IFN-g can promote inflammation and systemic insulin
resistance (Nishimura et al., 2009; Stolarczyk et al., 2013;
Wensveen et al., 2015; Winer et al., 2009). ILC2s express both
components of the IFN-g receptor (Robinette et al., 2015;
data not shown), and we found IFN-g directly represses ILC2
activation, cytokine production, and proliferation in vitro (Fig-
ure 6A, Figures S6A–S6C). Although ILC2s express receptors
for IL-10, IL-18, and IL-27 (data not shown), these cytokines
did not impair ILC2 activation by IL-33 (Figure S6D). In vivo,
lung tissue ILC2 proliferation and accumulation in response to
IL-33 were blocked by co-administration of IFN-g (Figure 6B),
and this was accompanied by decreases in ILC2 and Th2 IL-5
production (Figure 6C) and in Treg cell accumulation (Figure 6D).
Similar effects were noted in VAT (Figures S6E–S6G), although
the ability of a short course of IFN-g to repress IL-33-driven
ILC2 and Treg cell activation was less marked, possibly due
to the constitutively high expression of IL1RL1 by VAT ILC2s
and Treg cells. We could not detect IL1RL1 on NK cells or
CD8+ T cells either at rest or following challenge with IL-33 or
IL-33 and IFN-g; although IFN-g promoted CD8+ T cell and
NK cell proliferation, IL-33 alone had minimal effects (data not
shown).
To assess effects of endogenous IFN-g on ILC2 function, we
used Yeti mice (Stetson et al., 2003), in which the 30 untranslated
region (UTR) of IFN-g is stabilized by a YFP-bovine growth
hormone poly-A construct, leading to constitutive increases
in IFN-g; heterozygous mice were used here, thus avoiding
overt IFN-g-induced auto-inflammation (Reinhardt et al., 2015).
Similar to wild-type mice on high-fat diet (Molofsky et al.,
2013), young heterozygous Yeti mice on normal diet have fewer
total adipose tissue ILC2s, eosinophils, and Treg cells, show
attenuated IL-5 and ICOSL expression by ILC2s and rare Th2
cells, and accumulate NK cells, Th1 CD4+ T cells, and CD8+
T cells (Figures 6E–6I, Figure S6H, and data not shown). VAT168 Immunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc.Treg cells in Yeti mice express diminished levels of GATA3,
IL1RL1, KLRG1, andCD25 (Figure 6H). In the lung, where endog-
enous IL-33-driven type 2 immunity is constitutively less active
as compared to VAT, ILC2 numbers, and IL-5 production, eosin-
ophils and Treg cell were minimally affected in Yeti mice (Figures
S6I and S6J).
Next, we used knockin IFN-g reporter mice to identify NK
cells, CD4+ T cells, and CD8+ T cells as IFN-g-producing adi-
pose tissue cells under conditions of excess (Yeti mice; Fig-
ure S6K) and normal IFN-g (Great mice; Figure S6L) (Price
et al., 2012); accumulation of IFN-g-expressing CD4+ Th1 and
CD8+ T cells was particularly dynamic in resting VAT as
compared to lung. Indeed, wild-type IL-5 reporter mice older
than 15 months showed decreases in VAT, but not lung,
ILC2 numbers, IL-5 production, and eosinophil accumulation,
which correlated with increased inflammatory CD4+ and CD8+
T cells (Figure 7A, Figures S7A–S7C). VAT Tregs, which accu-
mulate in animals 4–9 months of age, decline with further aging
(Figure S7D). Similarly, young animals fed high-fat diet (HFD)
develop increased VAT IFN-g-producing T cells (Nishimura
et al., 2009; Stolarczyk et al., 2013; Winer et al., 2009) and
VAT-specific loss of IL-5+ ILC2 and Th2, eosinophils, and Treg
cells (Figure 7B, Figures S7E and S7F, data not shown).
Together, we conclude that VAT IL-33 promotes ILC2 activation
previously associated with metabolic homeostasis, including
the accumulation of Treg cells, and that IFN-g-producing lym-
phocytes infiltrate VAT in response to aging and high-fat diet
and repress ILC2-mediated function.
To assess the role of IFN-g in repressing ILC2 activation
during infection, we challenged heterozygous Yeti mice with
N. brasiliensis. Although helminth infection induces IL-33
(Moro et al., 2010), ILC2 proliferation, ILC2 and Th2 ICOSL ex-
pression and IL-5 production, and accumulation of KLRG1+
Treg cells, each of these responses was attenuated in
the lungs of Yeti mice (Figures 7C–7E, Figures S7G–S7I).
Helminth clearance from the gastrointestinal tract was also de-
layed (Figure 7F). To assess the effects of biologically induced
IFN-g, we infected mice with Listeria monocytogenes, intracel-
lular gram-positive bacteria that elicit potent IFN-g-mediated
responses necessary to clear infection. Listeria co-infection
with N. brasiliensis repressed lung ILC2s and KLRG1+ Treg
cell expansion, ILC2 and rare Th2 IL-5 production, and eosin-
ophilia (Figures 7G–7K), and promoted the accumulation of
CD8+ T cells (Figure 7G). These effects were dependent on
IFN-g, as IFNgR1 deficient co-infected mice did not display
impaired ILC2 activation or Treg cell expansion (data not
shown). Helminth infection is protective in mouse models of
type 2 diabetes (Hussaarts et al., 2015; Wu et al., 2011; Yang
et al., 2013), promoting short-term VAT ILC2 activation and
eosinophilia (Molofsky et al., 2013). We found that VAT
ILC2s, Th2, and eosinophils remain elevated 1 month after
helminth infection, and VAT eosinophils are elevated up to
10 months post-infection (Figures S7J and S7K). In contrast,
self-limited Listeria infection promotes persistent elevations in
VAT IFN-g-producing CD8+ T cells and decreased VAT ILC2
IL-5 production (Figure S7L). Together, we conclude that
IFN-g inhibits ILC2 activation and limits both the constitutive
IL-33-dependent maintenance of activated ILC2 and Treg cells
in VAT and the helminth- and IL-33-induced activation of ILC2s
Figure 6. IFN-g Represses ILC2 Activation and Limits IL-33-Driven ILC2s and Treg Cells
(A) Naive lung ILC2s (lin- thy1+ KLRG1+ CD25+) were sort purified and cultured in vitro with IL-2 and IL-33 with or without IFN-g for 3 days, and supernatants were
assayed for the indicated cytokines.
(B–D) Mice were treated with IL-33 ± IFN-g for three doses and lungs were assayed using flow cytometry for (B) ILC2 and Ki-67+ proliferating ILC2, (C) IL-5
production from ILC2 and CD4+ Th2, and (D) percent FoxP3+ Treg cells and total Treg cells (note secondary y axis on each).
(E–G) VAT from animals with constitutive excess IFN-g (Yeti3 Red5, gray dots) or wild-type (Red5) controls (black dots) were assayed by flow cytometry for (E)
IL-5+ ILC2 and IL-5+ Th2, (F) total ILC2 and eosinophils, or (G) percent FoxP3+ Treg cells of CD4+ T cells.
(H) VAT Treg cell expression of markers indicated from Yeti and wild-type animals.
(I) Representative FACS plots of VAT from wild-type IL-5 reporter and Yeti 3 IL-5 reporter mice. Data are representative of two to three experiments (H and I) or
pooled from two to three experiments (A–G). Error bars represent SEM.
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Figure 7. IFN-gAssociatedwithAge,Obesity, andListeria InfectionLimit ILC2-Mediated Immunity inAdiposeTissueandHelminth-InfectedLung
(A) VAT ILC2 and IL-5 expression (tdtomato MFI) were assessed in 15-month-‘‘old’’ and 8- to 12-week-‘‘young’’ IL-5 reporter (Il5tdtomato-cre/+) male mice.
(B) Mice were placed on normal diet or high fat diet (60% kCal fat) for 16 weeks and IL-5+ ILC2 were enumerated in VAT versus lung.
(C–E)Wild-type or Yeti IL-5 reporter mice were infected withN. brasiliensis and lung tissue harvested on days 7–9 post-infection, with the populations quantitated
by flow cytometry as indicated (note secondary y axis on each).
(F) N. brasiliensis were enumerated on day 9 post infection from small intestine of wild-type and Yeti mice.
(G–K) Wild-type IL-5 reporter mice were infected with N. brasiliensis, L. monocytogenes, or co-infected, and lung tissue harvested on day 7 post-infection, with the
populationsquantitatedbyflowcytometryas indicated (notesecondaryyaxisoneach).Dataarepooled fromtwoto threeexperiments (A–J).Errorbars representSEM.and Treg cells in lung. Further, our findings suggest adipose
tissue is a dynamic immunologic organ that retains a prolonged
‘‘metabolic memory’’ of diverse infections and may lead to last-
ing metabolic alterations for the organism.170 Immunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc.DISCUSSION
ILC2 cytokines, particularly IL-5 and IL-13, are critical in sustain-
ing the accumulation of eosinophils and AAMs necessary to
maintain adipose tissue homeostasis and local tissue responses
to perturbations mediated by allergens and helminths (Molofsky
et al., 2013; Odegaard et al., 2007; Walker and McKenzie, 2013;
Wu et al., 2011). Adipose tissue homeostasis and immunity to
helminths also involve tissue accumulation of Treg cells (Cipol-
letta et al., 2012; Feuerer et al., 2009; McSorley and Maizels,
2012), but mechanisms that link ILC2 activation and Treg
cells remain incompletely understood. Here, we identify IL-33
in coordinating ILC2s and Treg cell residence in resting VAT,
but also during tissue perturbations induced by systemic IL-2
treatment or during migratory helminth infection. Although Treg
cell activation by IL-33 was in part direct, as suggested by recent
studies (Schiering et al., 2014; Vasanthakumar et al., 2015),
optimal activation in vivo was ILC2-dependent by a process
requiring intrinsic ILC2 MyD88 and interactions between ICOSL
on ILC2s and ICOS on Treg. Although this IL-33-dependent
pathway may serve to protect adipose tissue or injured tissues
during allergen- or helminth-mediated injury, IFN-g produced
during acute inflammatory responses associated with infection
inhibited these processes, potentially providing an overriding
safeguard following invasion by rapidly replicating organisms,
such as bacteria or viruses. Chronic inflammation linked to
IFN-g in the setting of obesity and aging also attenuated the
normal organization of ILC2s and Treg cells in adipose tissue.
These data position IL-33, IFN-g, and ILC2s as critical regulators
in the balance between tissue injury, metabolic homeostasis,
and host defense.
Normal VAT contains high levels of IL-33 (Miller et al., 2010;
Zeyda et al., 2012), which we demonstrate in endothelial cell
nuclei in close proximity to resident ILC2s. Although others
have reported IL-33 in both endothelium (Zeyda et al., 2012)
and human adipocytes (Wood et al., 2009), our studies identify
endothelium as a predominant source in resting mice. IL-33
was necessary to sustain normal ILC2 function and Treg cell
numbers and function in VAT, as assessed in both IL1RL1- and
IL-33-deficient mice. Although necrotic cell death can release
IL-33, where it can be further activated by inflammatory prote-
ases (Cayrol and Girard, 2014), the mechanisms by which VAT
IL-33 titrates ILC2 and Treg cell function remain unknown. It is
intriguing that VAT, a dynamic storage for high-energy fuels,
would be a site constitutively impacted by IL-33, but perhaps
such localization serves to protect the host from the detrimental
metabolic effects of VAT inflammation. Recent reports have
called attention to the role of IL-33 in promoting adipose tissue
‘‘beiging’’ via activation of ILC2s, leading to increased heat pro-
duction and a loss of adipose tissue mass (Brestoff et al., 2014;
Lee et al., 2015). The relative metabolic contribution of IL-33-
induced beiging during normal physiology or cold-exposure is
unknown.
We previously reported that IL-2, which is used therapeutically
to expand Treg cells, activates ILC2 to proliferate, increase IL-5
production and promote eosinophilia (Van Gool et al., 2014).
Here, we also demonstrate that IL-2 synergizes with endoge-
nous IL-33 to promote expansion of IL1RL1+ KLRG1+ Treg cells,
a subpopulation with high suppressive capacity (Burzyn et al.,
2013b; Cheng et al., 2012; Feuerer et al., 2010; Wohlfert et al.,
2011). Such a mechanism may work to expand the local Treg
cell population and limit damage at immunologically active sites
where IL-2 and IL-33 co-localize following tissue injury andrecruitment or activation of IL-2 producing cells. IL-7, TSLP,
and IL-9 are cytokines that also signal through STAT5 and,
similar to IL-2, could cooperate with local IL-33 to enhance
Treg cell and ILC2 function.
Unexpectedly, expansion of Treg cells by IL-33 was optimally
dependent on ILC2s, as revealed using both IL-5- and IL-13-
driven cell deletion. Although we cannot rule out contributions
by small numbers of Th2 cells, which are partially deleted in
these mice, ILC2s comprise the vast majority of cells secreting
high levels of these cytokines under the conditions examined.
ILC2 cell-intrinsic IL-33 signaling was required for this effect,
as assessed using IL-5-mediated deletion of the MyD88 adaptor
protein. Treg-intrinsic IL-33 signaling was not necessary for Treg
cell expansion but was important in optimally sustaining KRLG1+
‘‘effector’’ Treg cells. Intriguingly, IL-4, IL-5, IL-9, and IL-13 were
not required to mediate effects of ILC2s on Treg cells, suggest-
ing that the downstream cellular targets of these cytokines, eo-
sinophils and AAMs, are also not necessary. Nonetheless, it is
possible that these cellular targets of ILC2s indirectly contribute
to Treg cell accumulation in certain models. We were unable
to implicate other ILC2-produced soluble mediators affecting
Treg cell activation, including IL-2, IL-10, and amphiregulin
(data not shown). Instead, we demonstrate that ILC2s and
Treg cells co-localize in tissues, raising the possibility that direct
interactions occur between these cells. Prior studies have called
attention to a role for ICOSL:ICOS in maintaining the survival of
tissue Treg cells (Redpath et al., 2013; Smigiel et al., 2014),
and we demonstrate that activated ILC2s express high levels
of ICOSL and are maintained in tissues for prolonged periods
after administration of IL-33 or migratory helminth infection. A
recent study also observed high levels of ICOSL on ILC2s,
finding ICOSL/ICOS autocrine signals can promote ILC2
STAT5 signaling to promote ILC2 numbers and function in an
asthma model (Maazi et al., 2015). We do not observe impaired
ILC2 or eosinophil numbers at rest of after systemic IL-33 admin-
istration in ICOSL-deficient C57BL/6 mice, although autocrine
signaling in ILC2s may be important in other contexts or strains.
We found that treatment with ICOSL-Fc and IL-33 failed to pro-
mote Treg cell accumulation in ILC2-deficient mice (data not
shown), and Treg cell expansion was compromised, but not
abolished, in the absence of ICOSL. Together, these findings
suggest ILC2s contribute to Treg cell expansion or maintenance
through additional pathways. Recent studies have reported that
innate lymphoid cells can express MHCII and perhaps present
antigen to CD4+ T cells (Hepworth et al., 2013; Oliphant et al.,
2014); such interactions, in combination with ICOSL co-stimula-
tion, could also contribute to Treg cell maintenance. Other VAT
immune cells, such as NKT cells, can produce IL-2 and may
also cooperate with ILC2 to maintain Treg cells (Lynch et al.,
2015). Of note, IL-33 alone can induce significant Treg cell pro-
liferation independently of ILC2s, suggesting that ILC2s act pri-
marily to promote the survival of Treg cells.
Although few inhibitory signals for ILC2s have been described,
IFN-g proved to be a potent inhibitor of ILC2 activation.
We demonstrate that resting ILC2s respond directly to IFN-g
in vitro, restricting both cytokine production and cellular prolifer-
ation. Although the mechanisms by which IFN-g restricts ILC2s
activation are unknown, IFN-g signals through STAT1 and
STAT2 and could repress the expression and/or phosphorylationImmunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc. 171
of GATA3 (Schiering et al., 2014). SOCS1 is highly elevated in
cells treated with IFN-g, and could also repress IL-33 signaling.
Although IL1RL1+ Treg cells in the colon were repressed directly
by IL-23 (Schiering et al., 2014), naive ILC2s are not inhibited by
IL-23 or IL-12 in vitro (data not shown). Lack of IFN-g signaling
has been associated with enhanced IL-5 and eosinophilia in
allergic models (Coyle et al., 1996) and patients with defects in
the IFN-g receptor have elevated immunoglobulin E and
increased atopic disease (Wood et al., 2005). Conversely,
IFN-g is effective in the treatment of atopic dermatitis (Reinhold
et al., 1993). Together, these results suggest that IFN-g is potent
at limiting both resting and pathologic type 2 immune responses,
although further work will be required to determine the specific
role of ILC2s and other leukocytes in these processes. IFN-g-
mediated immunity is beneficial in the context of life-threatening
infection, when pathogens must be contained andmetabolic en-
ergy diverted to glycolytic support of host defense. Indeed, our
data with bacterial/helminth co-infections suggest bacterial in-
fections limit helminth-induced ILC2 expansion and function. In
chronic obesity and aging, however, invasion of adipose tissues
by IFN-g-expressing lymphocytes, such as CD8+ T cells and Th1
cells, correlates with loss of adipose tissue ILC2s, Treg cells, eo-
sinophils, and AAMs (Molofsky et al., 2013) and the development
of systemic insulin resistance. Our data suggest these IFN-g-ex-
pressing lymphocytes can directly repress ILC2s, leading to
disruption of VAT metabolic homeostasis. As such, therapeutic
interruption of IFN-g signaling, possibly coupled with activation
of ILC2s, may provide a strategy for re-establishing adipose im-
mune homeostasis after obesity-driven dysregulation.
Our findings reveal novel interactions between ILC2s and Treg
cells, and raise questions regarding the underlying role and
function of ‘‘allergic immunity.’’ Increasingly, studies of these
pathways have uncovered interactions with basal metabolism,
mucosal homeostasis, and tissue repair (Burzyn et al., 2013b;
2013a; Cipolletta et al., 2012; Heredia et al., 2013; Molofsky
et al., 2013; Qiu et al., 2014; Schiering et al., 2014; Wu et al.,
2011). Not surprisingly, these pathways proceed independently
from activation of adaptive effector cells, which focus on path-
ogen-derived peptides presented during microbial invasion.
Prior studies have called attention to the destructive forms of
type 2 immunity that occur in the absence of Treg cells (Brunkow
et al., 2001; Fontenot et al., 2003) or following deletion of GATA3
or IRF4 in FoxP3+ lineage cells (Wang et al., 2011; Wohlfert et al.,
2011; Zheng et al., 2009). Although we have been unable to
document overt autoimmunity in IL-33- or IL1RL1-deficient
mice (data not shown), we speculate that the IL-33-ILC2-Treg
cell interactions we define may exist in part to protect local
tissues during injury ormicrobial invasion andmay be particularly
important at sites where excess or chronic inflammation is detri-
mental. In the right setting, however, IFN-g can suppress this
pathway to enable development of host defense against rapidly
proliferating microbes and perhaps contributes to the metabolic
shifts in fuel utilization that accompany inflammation. The thresh-
olds that define activation of these fundamental pathways in
distinct tissues may be underpinned by the endogenous levels
and regulation of IL-33, thus positioning this cytokine as a key
regulator linking ILC2 and Treg cells in protecting the host
during pathogen invasion or other challenges that disrupt tissue
integrity.172 Immunity 43, 161–174, July 21, 2015 ª2015 Elsevier Inc.EXPERIMENTAL PROCEDURES
Flow Cytometry
ILC2 are identified as lineage negative (CD11b, F4/80, CD3ε, CD4,
CD8a, CD19, Siglec F, FcεR1, NK1.1), FSC/SSC-low-to-moderate,
CD45+, CD127 (IL7Ra)+ or Thy1.2 (CD90.2)+, and IL1RL1 (ST2)+, CD25
(IL-2Ra)+, or KLRG1+, as indicated. CD4+ T cells are identified as FSC/SSC-
lo, CD45+, CD3ε+, CD4+. CD8+ T cells are identified as FSC/SSC-lo, CD45+,
CD3ε+, CD8+. Eosinophils are identified as CD45+, side-scatter high, DAPI-
lo, CD11b+, and Siglec F+. NK cells are identified as CD45+ CD3ε CD4
CD8 NK1.1+ CD11b variable. Treg cell are identified as CD45+ CD3ε+ CD4+
FoxP3+. In some cases, FoxP3GFP mice were used to identify Treg cell as
GFP+ CD4 cells. Populations were back-gated to verify purity and gating.
Samples were analyzed on an LSR II or, for cell sorting, a FACSAria II (both
BD Biosciences). Live lymphocytes were gated by DAPI exclusion, size, and
granularity based on forward- and side-scatter. Data were analyzed using
FlowJo software (TreeStar) and compiled using Prism (Graphpad Software).
Visceral adipose tissue (VAT) was normalized per gram adipose or as a percent
of total viable cells or percent of CD45+ hematopoietic cells, as indicated.
Immunofluorescence Microscopy
Animals were anesthetized and injected in vivo with 4% paraformaldehyde
(PFA). Tissues were harvested (VAT, lung, spleen, small intestine), fixed for
3 hr in 2% PFA, washed overnight with PBS, cryoprotected with 30% sucrose
for 12–36 hr, and embedded in OCT (Sakura Finetek) prior to freezing in blocks.
For whole mounts, tissues were fixed as above and imaged after permeabili-
zation with 0.4% triton X and DAPI nuclear counterstaining. Frozen sections
were processed on a Leica CM 3050S cryomicrotome (45 mm in VAT, 8 mm
all others), dried on slides for 30 min, and kept at 80 until staining. Tissues
were blocked with 5% goat or horse serum, and maintained in PBS + 5%
serum + 0.4% triton X throughout antibody treatments. Primary and secondary
antibodies were incubated for 1 hr at room temperature. Primary antibodies
used include goat-anti IL-33 (R&D Systems, 1:100), hamster-anti-KLRG1
(eBioscience, 1:50), anti-CD4-APC (BD Biosciences, 1:50), rat-anti-Siglec F
(BD Biosciences, 1:100), rat anti-CD31 (BD Biosciences, 1:100), chicken
anti-GFP (Aves labs, 1:500), or rabbit anti-dsRed (Clontech, 1:500). When
necessary, secondary antibodies were used at 1:1000 dilution. Slides were
mounted with Vectashield hardset mounting media. Where indicated, 5 min
before sacrifice, animals were injected with 20 mg anti-CD31-APC (Clone
390, eBioScience) to label the vasculature. Whole-mount tissue or slides
were examined with a Zeiss AxioVision M2 fluorescent microscope or a
laser-scanning confocal microscope (Nikon C1si), as indicated. Confocal im-
ageswere resolved to 1.2 mmper pixel in the xy plane and 1.0 mm in the z plane.
Infections
500 third-stage larvae of N. brasiliensis were injected subcutaneously as
described (Voehringer et al., 2006). Mice were killed at the indicated time
points and tissues were harvested and analyzed. Wild-type Listeria monocyto-
genes strain 10403s was infected intravenously (i.v.) at 3,000–4,000 CFU per
mouse.
Experimental Design and Statistical Analysis
All data were analyzed by comparison of means using unpaired two-tailed
Student’s t tests using Prism (GraphPad Software), with * = p < 0.05,
** = p < 0.01, *** = p < 0.001. Figures display means ± SE of the mean unless
otherwise noted. When possible, results from independent experiments were
pooled. All data points reflect individual biological replicates.
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